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reported relapses (p  0.001 for both); there was no association between SF-12 and 
physician reported frequency of relapses. PCS-12 was also signiﬁcantly associated with 
physician-assessed severity of relapse (p  0.002 for typical; p  0.001 for worst 
relapse, respectively) as well as patient-assessed severity of relapse (p  0.001 for 
typical; p  0.001 for worst relapse). Mental scores, however, were not signiﬁcantly 
associated with physician- or patient-reported relapse severity. CONCLUSIONS: As 
a generic HRQoL tool, the SF-12 was associated with relapses in an MS population. 
In patient-reported, as opposed to neurologist-reported, frequency of relapses was 
associated with a lower HRQoL. Patient- and neurologist-assessed severity of relapses 
was linked to a lower physical QoL. These observations suggest that relapses, both in 
quantity and severity, have a negative impact on HRQoL as measured by the SF-12.
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EVALUATION OF THE IMPACT OF PARKINSON’S DISEASE SYMPTOMS 
ON HEALTH-RELATED QUALITY OF LIFE. PD-QOL STUDY
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OBJECTIVES: The aim of this study was to evaluate the impact of symptoms related 
to Parkinson’s disease (PD) on health-related quality of life. METHODS: Observa-
tional, multicenter, cross sectional study in patients with PD, older than 18, who had 
received PD medication for at least 1 year before inclusion. The following assessments 
were applied: Hoehn and Yahr staging of PD (HY), SCOPA-Motor (SC-M), Non-
Motor Symptoms Questionnaire (NMSQ), QUICK Questionnaire (QQ, for detection 
of wearing-off, WO) and PDQ-39 to evaluate quality of life in PD patients. RESULTS: 
1.173 evaluable patients were included, 58.6% were males, mean age (SD) was 71.4 
(8.6) years and most of them were in HY stage 2 or 3 (70.3%). According to SC-M, 
94.5% patients presented rigidity, 93.1% rapid alternating hand movements and 
84.5% alteration of walking. Mean score of SC-M and NMSQ was 19.3 (12.6) and 
9.7 (6.1) points, respectively. Regarding the quality of life evaluated using the PDQ-39 
questionnaire, global score was 26.6 (18.6) points. Spearman correlation coefﬁcients 
between PDQ-39 and the other measures were: HY, 0.55; SC-M, 0.76; NMSQ, 0.73; 
and QQ, 0.67. 59.2% patients presented WO according to QQ. Quality of life was 
better for patients without WO: PDQ-39 score 20.0 (17.4) vs 30.8 (18.2) points in 
patients with WO (p  0.0001). CONCLUSIONS: The results of this study suggest 
that Parkinson’s disease patients present a combination of motor and no-motor 
symptoms which affects quality of life. The presence of wearing off affects also the 
quality of life of these patients.
NEUROLOGICAL DISORDERS – Health Care Use & Policy Studies
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PROLONGED-RELEASE MELATONIN: REAL-LIFE EVIDENCE FROM A 
GERMAN LONGITUDINAL PRESCRIPTION DATABASE
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OBJECTIVES: Benzodiazepines and Z-drugs are extensively prescribed in patients 
with insomnia, and their use raises public health concerns of dependence and increased 
indirect costs (e.g., falls). The aim of this study was to investigate prescribing practice 
patterns of Prolonged-Release Melatonin (PRM), a newly licensed hypnotic, in real-life 
settings using longitudinal prescription database analyses. METHODS: Longitudinal 
data of patients initiating PRM was extracted from a primary care prescription data-
base in Germany (IMS-DA). Patient characteristics (age, gender) and treatment infor-
mation (drug name, prescription date, number of packages and indication) were 
retrieved. Descriptive analyses investigated the proportion of patients with or without 
a past history of hypnotic use (deﬁned as at least one benzodiazepine or Z-drug (BZD-
Z) prescription within 3 months prior to PRM initiation). Descriptive statistics identi-
ﬁed the proportion of patients with or without BZD-Z prescriptions within the 3 
months following treatment initiation. Sensitivity analyses were performed on longer 
follow-up periods (6 months) and higher numbers of previous BZD-Z prescriptions 
(at least 2) to test the robustness of the ﬁndings. RESULTS: 1,382 eligible patient 
records were retrieved. Two-thirds were female (mean age 62). Among them, 512 
patients had a minimum 3-month history and 3-month follow-up. Approximately 
80% were not prescribed BZD-Z before PRM initiation and of those, 90% were still 
not prescribed any BZD-Z after 3 months. Among previous BZD-Z users, results 
showed that approximately 1/3 (36/112) were not prescribed any BZD-Z medication 
3 months after PRM initiation. Results were substantiated by sensitivity analyses on 
both longer follow-up duration and a greater number of previous BZD-Z prescrip-
tions. CONCLUSIONS: PRM might represent an interesting alternative to BZD-Z use 
for the treatment of insomnia. Further research with a larger study population is 
needed to conﬁrm these results.
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BACKGROUND: Chronic inﬂammatory demyelinating polyradiculoneuropathy 
(CIDP) is an acquired immune-mediated inﬂammatory disorder that targets the myelin 
sheaths of the peripheral nervous system. Intravenous immunoglobulin (IVIg) is a 
blood product containing immunoglobulin G (IgG) that has been pooled from many 
human donors. In the fall of 2008 CIDP became an approved indication for IVIg in 
both Canada and the United States. OBJECTIVES: To evaluate the clinical effective-
ness and safety of IVIg for the treatment of CIDP through a systematic review of the 
literature. METHODS: The Medline (1950–2009; In-Process & Other Non-Indexed 
Citations) and EMBASE (1980–2009) databases were searched through the Ovid 
interface. A methodological ﬁlter was applied to limit retrieval to clinical trials, MAs, 
or SRs. Retrieval was limited to humans and no language restrictions were employed. 
Extracted data were pooled to estimate the effect size of IVIg treatment based on the 
random-effects model. RESULTS: Nine unique RCTs were identiﬁed. Three of the 
nine trials compared IVIg therapy to an active comparator (plasma exchange (PE), PE 
using extracorporeal immunoadsorption, or oral prednisolone), and the other six trials 
were placebo-controlled. There was no incremental beneﬁt seen in the primary out-
comes when comparing IVIg therapy and the active comparator. Five of the six 
placebo-controlled trials showed IVIg therapy to be superior to placebo based upon 
a variety of disability or impairment outcomes. CONCLUSIONS: IVIg therapy is sta-
tistically superior to placebo treatment in reducing the disability and impairment for 
CIDP patients. IVIg demonstrates similar effectiveness as the alternative treatment 
strategies of PE and methyprednisolone.
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DISEASE MEDICATIONS
Oremus M, Tarride JE, Raina P, Clayton N
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OBJECTIVES: In Canada, public drug plans provide limited reimbursement for 
Alzheimer’s disease (AD) medications. For most Canadians, the cost of these medica-
tions is paid ‘out-of-pocket’. This study was conducted to assess the Canadian general 
public’s willingness-to-pay (WTP) for unrestricted access to AD medications. 
METHODS: Five-hundred participants (age q18 years) were recruited nationally and 
stratiﬁed by income. Data were collected via computer-assisted telephone interviews. 
Participants were presented with four ‘efﬁcacy’ scenarios describing a hypothetical, 
new AD medication. In two scenarios, the medication was described as modifying the 
symptoms of cognitive decline. In the other two scenarios, the medication was 
described as halting disease progression. For each pair of ‘efﬁcacy’ scenarios, the 
medication was assumed to have no adverse effects in one scenario and a 30% chance 
of adverse effects in the other scenario. For every scenario, participants were asked 
whether they would support unrestricted access to the medication through an annual 
increase in personal income taxes. Participants then provided the maximum tax 
increase that they would support. WTP was elicited using a bid range: $75, $150, or 
$225. Open-ended questions allowed participants to specify values outside the range. 
Participants were randomized to order of scenarios and bids. Differences between 
scenarios were assessed using Bowker’s test of symmetry. RESULTS: Overall, 80% of 
participants (n  398) supported a tax increase under at least one scenario. Maximum 
WTP did not differ across scenarios (median  $150, interquartile range  $75 to $225 
[for all four scenarios]). After categorization ($75, $75, $150, $225,  $225), the 
distribution of maximum WTP did not differ by efﬁcacy (symptom modiﬁcation versus 
halting disease progression [p  0.34]) or adverse effects (30% chance versus none 
[p  0.54]). CONCLUSIONS: Most participants reported support for a tax increase. 
Once the decision was made to support an increase, maximum WTP was unaffected 
by efﬁcacy or the potential for adverse effects.
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STUDY OF THE GENERAL POPULATION
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OBJECTIVES: In Canada, the cost of Alzheimer’s disease (AD) medications is mainly 
borne by patients and caregivers. The primary objective of this study was to measure 
the Canadian general public’s support for a program of unrestricted access to AD 
medications. The secondary objective was to identify determinants of support for the 
program. METHODS: A national sample of 500 Canadians, aged 18 years or older, 
was randomly recruited to participate in a computer-assisted telephone interview. The 
sample was stratiﬁed by income. Participants were presented with a set of randomly-
ordered scenarios describing a hypothetical, new AD medication. The efﬁcacy of the 
medication was varied by scenario: the medication was alternately described as modi-
fying the symptoms of cognitive decline or actually halting disease progression. The 
adverse effects proﬁle was also varied in the scenarios: no adverse effects or a 30% 
chance of some adverse effects. For each scenario, participants were asked whether 
they supported an annual increase in personal income taxes to fund unrestricted access 
to the AD medication. Logistic regression was conducted to identify factors that might 
explain support for the tax increase. RESULTS: Percentage of respondents supporting 
a tax increase varied with scenario: symptom modiﬁcation and 30% chance of adverse 
effects  49% (n  244); symptom modiﬁcation, no adverse effects  58% (n  290); 
halt progression and 30% chance of adverse effects  54% (n  270); halt progression, 
no adverse effects  67% (n  333). Relative to the ‘symptom treatment and 30% 
chance of adverse effects’ scenario, the level of support was different (p  0.05) for 
all except the ‘halt progression and 30% chance of adverse effects’ scenario (p  0.15). 
No determinant (e.g., age, sex) could consistently explain support across all four 
 scenarios. CONCLUSIONS: Support for the tax increase varied by the efﬁcacy and 
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adverse effects proﬁle of the medication. The most support was registered for the 
optimal scenario (halt disease progression, no adverse effects).
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MIGRAINE: PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY 
CARE PATIENT POPULATION
Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa
OBJECTIVES: Migraine affects 8% to 14% of the population in Western countries. 
It affects primarily the young adult population and is responsible for many lost 
working days each year since it affects primarily the economically active sector of the 
community. The primary aim of the study was to determine the prescribing patterns 
and cost of drugs for migraine in a primary care patient population. METHODS: A 
retrospective drug utilisation consumption study was conducted. Data were obtained 
from a South African private health care group. The database consisted of all central 
nervous system medicine for 2008. RESULTS: A total of 22102 patients (71.05% 
females) received 43144 items for migraine a cost of R3622552 (average cost of 
R83.96 per item). The average age of patients was 44.90 (SD  13.83) years, with 
70.76% of patients between 30 and 59 years of age. The chi-square test was used to 
detect prescribing differences between female and male patients in different age groups 
(chi2  212.31; d.f.  6; p  0.0001). Differences were observed in prescribing to female 
and male patients. Patients were prescribed an average of 1.95 items for migraine over 
the year. The Lorenz curve was used to illustrate skewness in prescribing. Clonidine 
was the most frequently prescribed active ingredient (46.15%), followed by cyclizine 
(29.62%). The agents for the prophylaxis of migraine (clonidine, ﬂunarizine and 
pizotifen) accounted for 50.48% of prescribing frequency and 29.04% of cost. The 
selective 5HT1-receptor agonists (triptans) accounted for 18.94% of prescribing fre-
quency and 53.54% of cost. Rizatriptan was the most frequently prescribed triptan. 
CONCLUSIONS: The ﬁndings were generally in agreement with two other South 
African studies, although differences were observed. A lower prescribing rate for 
triptans has been observed. Qualitative studies on migraine are needed in South Africa 
to determine its impact on the quality of life of patients.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
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SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF 
PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN
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OBJECTIVES: Chronic low back pain (CLBP) is a major cause of disability, affecting 
mainly working-age adults and imposing a large economic burden on society. Since 
no consensus exists regarding standard of care for this condition, the objective of this 
study was to systematically review the efﬁcacy and safety of pharmacotherapies used 
for CLBP. METHODS: A systematic literature review was conducted through July/
August 2008, searching MEDLINE, EMBASE, and bibliographic details of relevant 
studies. Prospective trials and observational studies were included if they assessed 
pharmacotherapies in adults with CLBP and were written in English. Efﬁcacy end-
points included: pain relief, pain interference with activities, individual’s functioning 
and response to treatment. Adverse event (AE) rates and withdrawal rates due to AEs 
were also assessed. Extensive study heterogeneity prohibited quantitative synthesis. 
RESULTS: From 773 citations screened, 65 studies (published between 1982 and 
2008) were selected, of which 54 were randomized controlled trials. The efﬁcacy 
measures most consistently reported across studies included the visual analogue scale 
(VAS) and the Roland Morris Disability Questionnaire (RMDQ). Non-steroidal 
anti-inﬂammatory drugs (NSAIDs), weak and strong opioids, several antidepressants 
(clomipramine, mianserin, and duloxetine titrated based on patient response and toler-
ability), the anticonvulsant topiramate, and certain transdermal medications (trans-
dermal fentanyl and lidocaine patches) signiﬁcantly reduced pain intensity. The 
effectiveness of injections (i.e., glucose and lidocaine) and other antidepressants (par-
oxetine, trazodone or bupropion) was uncertain. Regarding patient functioning, sig-
niﬁcant improvements were observed for NSAIDs, opioids and duloxetine, but not for 
local injections. The magnitude of effect of these endpoints ranged from small to 
moderate, depending on the pharmacotherapy assessed. CONCLUSIONS: NSAIDs, 
opioids, some antidepressants, an anticonvulsant and certain transdermal medications 
seemed to signiﬁcantly reduce pain intensity in CLBP, while inconclusive results were 
obtained for other antidepressants and local injections. Overall, the study ﬁndings 
were consistent with current guideline recommendations from Europe and US.
PSY2
EVALUATING ADVERSE EVENT RISK WITH PROPOXYPHENE: ARE 
THERE DIFFERENCES BETWEEN ELDERLY VERSUS YOUNGER 
PATIENTS?
Bharmal M1, Garvert W2, Jo H2, Gemmen EK1, Hall JR3
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OBJECTIVES: Propoxyphene is among the most commonly prescribed opioid anal-
gesic in the elderly. However, many guidelines, including the American Geriatric 
Society and Beer’s List of Potentially Inappropriate Medications, recommend restrict-
ing its use in that age group. These guidelines are based on expert opinions with limited 
empirical evidence. The objective of this study was to evaluate whether there were 
differences in adverse event reporting for propoxyphene by age group using a large 
post-marketing safety surveillance data. METHODS: Analysis was conducted using 
the 2005–2008 Adverse Event Reporting System (AERS) data in the US, which was 
developed to support the FDA’s post-marketing safety surveillance program for all 
approved products. Adverse events reported with propoxyphene as primary, second-
ary or interacting drug were categorized into central nervous system (CNS) and gas-
trointestinal (GI) adverse events (AEs). Logistic regressions were used to assess the 
risk of CNS and GI adverse events (AEs) among the elderly (age   65) and younger 
patients (age  65) controlling for gender and those reporting the AEs. Proportional 
reporting ratios (PRR) for the propoxyphene-AE combination were also computed for 
the elderly and younger patients. RESULTS: In the period 2005–2008, a total of 2497 
propoxyphene-AE combinations were reported, 261 were CNS-related and 127 were 
GI-related. In multivariate analysis, controlling for gender and those reporting the 
AEs, no signiﬁcant differences were observed in the risk of CNS-related AEs (Odds 
ratio: 0.827; 95% CI: 0.619–1.105; p  0.199) or GI-related AEs (Odds ratio: 1.216; 
95% CI: 0.832–1.778; p  0.313) among elderly versus young patients. Among the 
elderly, the PRR for propoxyphene-CNS AEs was 0.795 and the PRR for propoxy-
phene-GI AEs was 0.596. These were similar to the PRRs among younger patients, 
which were 0.700 and 0.439, respectively. CONCLUSIONS: Using a voluntary post-
marketing surveillance database, the study found no differences in the extent of CNS 
AEs and GI AEs reported with propoxyphene among elderly patients versus younger 
patients.
PSY3
DETERMINING THE COST OF OBESITY AND ITS MAJOR 
COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE
Padula WV, Nair KV
University of Colorado at Denver and the Health Sciences Center, Aurora, CO, USA
OBJECTIVES: To determine payments made by commercial health care providers for 
adults diagnosed with obesity, and those who are comorbid with any combination of 
the following chronic conditions: diabetes mellitus (DM), hypertension, depression, 
and/or congestive heart failure (CHF). METHODS: We utilized a 10% random sam-
pling from a commercial claims and encounters database (n  12,416,190). The study 
population (n  50,717) was limited to those who: 1) were adults age 18–64; 2) ﬁled 
a claim between 2006–2007; 3) had at least one inpatient visit, one outpatient visit, 
or one emergency department visit; and; 4) had been given a primary or secondary 
diagnosis of obesity. Persons were identiﬁed and categorized if they had one or more 
comorbid diagnoses (DM, hypertension, depression, and/or CHF) in addition to 
obesity. After adjusting for age and gender, we calculated the mean total net expen-
ditures (in $US 2007) for each combination of comorbid conditions. All calculations 
were performed in Stata. RESULTS: Among those diagnosed with obesity, the mean 
net expenditures for services were $1799 per patient. Persons diagnosed with obesity 
and other comorbidities observed an increase in total net expenditures. Obesity and 
hypertension observed the highest increase among single comorbidities at $4298. For 
persons with obesity and two other comorbidities, DM and depression was the highest 
at $14,364. The most expensive condition in the study sample was obesity, DM, 
hypertension and depression at $14,843. All results were statistically signiﬁcant at the 
95% conﬁdence level. CONCLUSIONS: Compared to the average medical claim, 
persons diagnosed with obesity along with other common chronic conditions experi-
ence signiﬁcant increases in health care costs. These costs are often driven higher by 
the time spent as inpatients. In many cases, obesity may be the cause of other chronic 
conditions that result in these high costs. Thus, by controlling and reducing the preva-
lence of obesity, we may see signiﬁcant decreases in health care expenditures.
PSY4
CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE 
OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT 
PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA
Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B
Erasmus MC, Rotterdam, The Netherlands
OBJECTIVES: Treatment of patients with acute myeloid leukemia (AML) is based 
upon stratiﬁcation into risk (prognosis) groups. New diagnostic methods are in devel-
opment to improve this stratiﬁcation. Economic evaluations of these methods require 
knowledge of what happens when the current stratiﬁcation methods are used. We 
examined whether the literature can provide valid estimates for the outcomes 
of complete remission rates for patients with primary AML aged 16–60 years. 
METHODS: A systematic literature review was performed using Pubmed and Embase. 
Inclusion criteria were: q100 AML patients and detailed outcomes per risk group 
(favorable, intermediate, unfavorable). Excluded were: Phase I/II studies, studies not 
containing any patients aged 16–60 years or with primary AML. We compared various 
study characteristics such as patient population, treatment given, risk group deﬁnitions 
and complete remission (CR) rates as outcome. A chi-square test for homogeneity of 
CR rates was performed. RESULTS: Twelve studies fulﬁlled the eligibility criteria. 
Great variation was found between study populations. While treatment varied between 
the studies, all patients received cytarabine and an anthracycline. Deﬁnitions of risk 
groups varied greatly except for the favorable risk group. There was no homogeneity 
in overall CR rate (range: 52–85% p  0.001). After excluding studies with many 
patients other than the target population, heterogeneity between the remaining studies 
decreased (N  7, p  0.083). CR rates were homogeneous in the favorable group (p 
 0.223), but heterogeneous in the intermediate and unfavorable groups (p  0.044 
and p  0.096 respectively). CONCLUSIONS: Differences in patient population and 
